Background: Patients with castration-resistant prostate cancer derive only modest clinical benefit from available therapies. Blockade of the inhibitory programmed death 1 (PD-1) receptor by monoclonal antibodies has been effective in several malignancies. Results from the prostate adenocarcinoma cohort of the nonrandomized phase Ib KEYNOTE-028 trial of pembrolizumab in advanced solid tumors are presented.
Introduction
Prostate cancer is the second most common cancer in men, accounting for 10.7% of new cancer cases, and is the fifth-leading cause of cancer-related death; an estimated 307 000 deaths occurred in 2012 (6.6% of all cancer-related deaths in men) [1, 2] . The overall 5-year survival rate for those with metastatic disease is only 29.3% [1] .
In metastatic castration-resistant prostate cancer (mCRPC), treatment options that have improved overall survival (OS) include novel hormonal agents, immunotherapy with sipuleucel-T, chemotherapy, and radium-223 [3] . However, toxicity is common with these agents, benefits are rarely durable, and none of these therapies are curative.
The programmed death 1 (PD-1) receptor pathway is important for inducing immunosuppression and immune tolerance present in the tumor microenvironment and other tissues [4, 5] . Expression of the PD-1 ligand (PD-L1) has been demonstrated in many tumor types and leads to the inhibition of tumor-directed T-cell responses [4] . Strong expression of PD-1 on tumorinfiltrating T cells has been reported in prostate cancer, and it is associated with rapid tumor progression [6] [7] [8] . Reports on the expression of PD-L1 on tumor and stromal cells have been conflicting, with expression varying from lack of expression to low and high expression [7, [9] [10] [11] [12] . Similarly, the association between PD-L1 expression and outcomes is variable, with some studies reporting a significant association between high PD-L1 expression and poor outcomes [7, 11] and others reporting no association [10] . Pembrolizumab is a humanized immunoglobulin (Ig) G4 monoclonal anti-PD-1 antibody that binds to the PD-1 receptor, blocking interaction with its ligands on cancer cells, immune cells, and stromal cells, thus counteracting PD-1 pathwaymediated inhibition of the immune response [7, 13] . In the phase Ib KEYNOTE-028 trial, antitumor activity and safety of pembrolizumab monotherapy in PD-L1-positive advanced solid tumors were evaluated, and results from the prostate adenocarcinoma cohort are reported herein.
Methods

Study design and procedures
KEYNOTE-028 (NCT02054806) is a multicenter (16 sites) , open-label, phase Ib trial designed to evaluate efficacy and safety of pembrolizumab for treatment of patients with PD-L1-positive advanced solid tumors. Study protocol and all amendments were approved by institutional review boards or ethics committees of all participating sites, and the study was conducted in accordance with International Conference on Harmonisation for Good Clinical Practice guidelines and the Declaration of Helsinki. All enrollees provided written informed consent.
Patients. Eligible patients were aged 18 years with histologically or cytologically documented, locally advanced or metastatic prostate adenocarcinoma that was incurable and for which standard therapy was ineffective or not considered appropriate; at least one measurable lesion at baseline [irrespective of prostate-specific antigen (PSA) levels] after last line of cancer therapy based on Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) [14] ; PD-L1 expression in 1% of tumor or stromal cells; Eastern Cooperative Oncology Group performance status 0/1; and adequate organ function, determined by laboratory testing within 10 days of first pembrolizumab dose. Patients with prostate cancer who were receiving luteinizing hormone-releasing hormone (LHRH) analogs were eligible for this study and could continue their therapy at the investigator's discretion. Exclusion criteria are listed in the supplementary material, available at Annals of Oncology online.
Treatment and assessments
All enrolled patients were administered pembrolizumab 10 mg/kg once every 2 weeks. Treatment continued for 24 months or until confirmed disease progression (PD), unacceptable adverse events (AEs), or investigator or patient decision to withdraw. In the case of radiographic PD [i.e. two scans 28 days apart demonstrating PD (20% increase in the sum of target lesions as per RECIST v1.1 [14] )] patients who were clinically stable or had improved and showed no further increase in tumor dimensions on confirmatory imaging could continue treatment after consultation with the sponsor. Treatment interruption, discontinuation, and retreatment criteria are described in the supplementary material, available at Annals of Oncology online.
Patients were evaluated radiographically (e.g. computed tomography or magnetic resonance imaging) at baseline (per RECIST v1.1) within 28 days before the first dose of pembrolizumab. Tumor response to pembrolizumab was then evaluated every 8 weeks for the first 6 months of the study and then every 12 weeks thereafter per RECIST v1.1. PSA levels were not mandated by protocol; therefore, not all patients had serial PSA collections. Safety assessments and PD-L1 expression analyses are described in the supplementary material, available at Annals of Oncology online.
End points
The primary efficacy end point was objective response rate (ORR), the proportion of patients who experienced complete response (CR) or partial response (PR) per RECIST v1.1 (investigator review; Prostate Cancer Clinical Trials Working Group criteria were not used for response assessment for this cohort) at any time during the study. Secondary end points were safety and tolerability, duration of response (DOR), progressionfree survival (PFS), and OS. PSA responses were evaluated as an exploratory end point.
Statistical analyses
The full-analysis-set (FAS) population served as the primary population for efficacy analyses; the FAS population comprised all patients who received at least one dose of pembrolizumab and had measurable disease at baseline per RECIST v1.1. The all-patients-as-treated population, used for safety analyses, included all patients who received at least one dose of pembrolizumab.
ORR was evaluated within each cohort of the overall study using a sequential monitoring approach [15] . Cohorts not closed for futility were to enroll at least 22 assessable patients per cohort, which would provide 80% power to demonstrate that the best ORR exceeded 10% at an overall one-sided 8% alpha level if true best ORR for a cohort were 35%. The Kaplan-Meier method was used to analyze PFS, OS, and DOR. Data cutoff was 20 February 2017.
Results
Patient baseline characteristics and treatment
Of 245 screened patients with prostate cancer, 35 (14.3%) had PD-L1-positive tumors; 23 of 35 were enrolled and received at least one dose of pembrolizumab. Median age was 65 years (range 46-83 years), and seven patients (30%) received five or more therapies (Table 1) . At study entry all patients had castraterefractory disease: 22 men had medical androgen deprivation therapy and 1 man underwent bilateral orchiectomy. For all patients, PD-L1 status was assessed on archival tissue; 12 patients (52.2%) had PD-L1 expression in the tumor only, and 11 (47.8%) had PD-L1 expression in the stroma only. No patients had both tumor and stromal expression of PD-L1.
At data cutoff, median follow-up was 7.9 months (range 1.4-30.3 months), and 22 patients (95.7%) discontinued pembrolizumab because of PD (n ¼ 15, 65.2%), an AE (n ¼ 1, 4.3%), or withdrawal by patient or physician (n ¼ 6, 26.1%; supplementary Figure S1 , available at Annals of Oncology online).
Antitumor activity PR was confirmed for four patients, for an ORR of 17.4% [95% confidence interval (CI) 5.0%-38.8%] ( Table 2) . One patient experienced PR (unconfirmed), yielding an unconfirmed and confirmed ORR of 21.7% (95% CI 7.5%-43.7%). No CRs occurred, and a confirmed best response of stable disease (SD) and PD was observed for 8 (34.8%) and 9 (39.1%) patients, respectively (see supplementary Table S1 , available at Annals of Oncology online for additional responder details). Responses were not assessable or not assessed for two patients. Of responders, two had PD-L1 expression in the tumor only and two had PD-L1 expression in the stroma only. Eighteen patients continued to receive an LHRH analog while receiving pembrolizumab.
Reduction in tumor size from baseline (sum of the longest diameters of target lesions over time) was found in 10 of 21 assessable patients ( Figure 1A) ; this reduction was durable in all four responders ( Figure 1B) ; median DOR was 13.5 months (95% CI 6.5-14.2 months) ( Table 2) . Median time to response was 2.7 months (95% CI 1.8-5.7 months). At data cutoff, one patient remained on treatment and experienced PR ( Figure  1C) . Three of four patients with confirmed PR experienced parallel biochemical response, defined by a >50% PSA decrease.
Median PFS was 3.5 months (95% CI 1.7-6.5 months), with 6-and 12-month PFS rates of 34.8% and 17.4%, respectively (Figure 2A ). Median OS was 7.9 months (95% CI 6.5-not reached), with 6-and 12-month OS rates of 73.4% and 36.7%, respectively ( Figure 2B ). Responses were not evaluable or not assessed for two patients.
c Patients achieved radiographic stable disease but discontinued treatment because of clinical progression.
Safety
Fourteen patients (60.9%) experienced treatment-related AEs (TRAEs); nausea was the most frequent (n ¼ 3, 13.0%). Three (13.0%) patients experienced grade 3 TRAEs (n ¼ 1 each for peripheral neuropathy, asthenia, and fatigue), and one (4.3%) experienced a grade 4 TRAE (increased lipase) ( Table 3) . Immune-mediated AEs were experienced by two patients: grade 2 hypothyroidism in one and grade 1 urticaria in the other; urticaria was considered related to pembrolizumab by the investigator. No deaths or treatment discontinuations occurred because of TRAEs.
Discussion mCRPC is incurable despite multiple therapies improving OS. In the current study, pembrolizumab monotherapy demonstrated antitumor activity in a subset of patients with advanced PD-L1-positive prostate adenocarcinoma that progressed on standard therapies, and the safety profile was acceptable. Responses were durable, lasting more than 1 year in most patients, with one patient having ongoing SD for over 20 months of treatment. Tumor PD-L1 expression, which was low in prostate cancer compared with other tumor types such as non-small-cell lung cancer [16] or bladder cancer [17] , was used as a selection criterion because this was a signal-finding study design. Therefore, true response rate in an unselected population is not known. PD-L1-negative tumors have responded to PD-1/PD-L1 inhibition in other solid tumors (e.g. melanoma) [18, 19] . In the current study, expression of PD-L1 occurred in 14.3% of tumors, whereas, in other analyses, PD-L1 expression has been reported in 0% to 100% of prostate tumors [7, [9] [10] [11] . This variability is likely because of differences in disease status and the different antibody clones, platforms, and scoring criteria used [7, [9] [10] [11] . Pembrolizumab was well tolerated, and its safety profile is consistent with that observed previously [18, 20] , with no treatmentrelated discontinuation or death. There were only three grade 3 and one grade 4 TRAEs, none resulting in discontinuation. Peripheral neuropathy is not generally observed with pembrolizumab. Although this symptom did not arise until cycle 4 of treatment, it may be a delayed phenomenon from prior docetaxel chemotherapy [21] .
The immunosuppressive microenvironment of prostate cancer results in inhibition of tumor-specific T-cell responses, facilitating tumor invasion and growth [22, 23] . In the prostate tumor bed, natural killer (NK) cells have low cytolytic activity [24] ; high levels of tumor growth factor (TGF)-beta secretion in prostate tissue demonstrated NK cell and lymphocyte inhibition [25] ; and recruitment of T-regulatory cells and T-helper (Th) 17 lymphocytes in the prostate gland that downregulate antitumor immunity [26] . Myeloidderived suppressor cells also play a role in creating the immunosuppressive microenvironment in prostate cancer [27] . PD-L1 expression was identified as an independent indicator of biochemical recurrence in primary prostate cancer [7] . The potential of immune checkpoint inhibitors as treatment in this patient population has been suggested by recent studies [31] [32] [33] . In studies of ipilimumab versus placebo after radiotherapy in postchemotherapy mCRPC [28] and chemotherapy-naive CRPC [29] , ipilimumab did not improve OS [28, 29] . However, an exploratory piecewise hazards model [28] suggested a reduction in the hazard ratio for OS over time that ultimately favored ipilimumab. In an ongoing phase II trial of pembrolizumab plus enzalutamide in patients with mCRPC with evidence of progression on enzalutamide, a near-complete PSA response was observed in 3 of 10 patients; two achieved PR [30] . Although PSA response was only evaluated as an exploratory end point in the current study, ORR is a reasonable signal-seeking end point. Future analyses should evaluate PSA response as an efficacy end point. Counter to the experience with patients who experienced progression on enzalutamide, all four responders in the current trial had chemotherapy as the last line of treatment before pembrolizumab. Recent studies also suggest that responses to immune checkpoint inhibitors may only occur in subgroups of patients, such as mCRPC patients with microsatellite instability or mCRPC patients with ARV7-positive tumors [31, 32] . Median OS reported in landmark clinical trials in mCRPC that established new standards of care for prostate cancer ranged from 9.0 to 35.3 months [33, 34] . OS with pembrolizumab was shorter (7.9 months), but patients were heavily pretreated. The clinical state of the KEYNOTE-028 prostate cancer patients was more advanced than those in the aforementioned trials, likely leading to shorter OS. Investigation of pembrolizumab monotherapy and in combination with other anticancer agents, in an unselected PD-L1 patient population restricted by prior lines of therapy to permit a homogeneous patient cohort, may identify specific subgroups of patients who might derive benefit.
The current findings show an acceptable safety profile for pembrolizumab monotherapy and preliminary evidence of antitumor activity in patients with PD-L1-positive advanced prostate adenocarcinoma. The clinical benefit of pembrolizumab is being explored as monotherapy in the phase II KEYNOTE-199 study (NCT02787005) and as combination therapy in the multicohort phase I KEYNOTE-365 study (NCT02861573).
